Otsuka Holdings Co Ltd (JP:4578)
:4578
Want to see JP:4578 full AI Analyst Report?
4578 Stock Chart & Stats
¥8150.00
-¥102.00(-1.20%)
At close: 4:00 PM EST
¥8150.00
-¥102.00(-1.20%)
Day’s Range― - ―
52-Week Range¥6,511.00 - ¥11,660.00
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.11M
Market Cap
¥6.02T
Enterprise Value¥5.83T
Total Cash (Recent Filing)¥538.30B
Total Debt (Recent Filing)¥194.63B
Price to Earnings (P/E)14.8
Beta0.64
Next Earnings
Jul 30, 2026EPS Estimate
148.05Next Dividend Ex-DateN/A
Dividend Yield1.42%
Share Statistics
EPS (TTM)713.14
Shares Outstanding542,988,900
10 Day Avg. Volume977,130
30 Day Avg. Volume1,112,043
Financial Highlights & Ratios
PEG Ratio1.60
Price to Book (P/B)1.55
Price to Sales (P/S)1.91
P/FCF Ratio14.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥12,458.00Price Target Upside52.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)583.69
Revenue Forecast (FY)¥2.57T
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ExpansionSustained top-line expansion and improved gross and operating margins versus the 2022–2023 trough indicate the company is regaining pricing power and product mix advantages. This supports durable internal funding for R&D and lifecycle management, strengthening long-term competitiveness.
Conservative Balance Sheet, Low LeverageVery low debt relative to equity provides financial flexibility to fund clinical programs, acquisitions, or capital spending without stressing liquidity. A strong balance sheet also lowers refinancing risk and preserves capacity to support long-term strategic investments.
Diversified Pharmaceuticals And Consumer-health ModelA two-pronged revenue model (innovative drugs plus consumer health/nutraceuticals) smooths cyclicality and provides multiple cash engines. Consumer products offer steady retail cash flow while pharma investments can deliver high-margin growth when clinical projects succeed, improving resilience.
Bears Say
Operating Cash Flow Below Net IncomePersistent OCF substantially below reported net income suggests working-capital timing or noncash income items that reduce cash available for reinvestment. Over time this can constrain funding for capex, R&D, dividends or buybacks despite strong accounting earnings.
Recent Free Cash Flow Weakness And VolatilityVolatile and recently negative FCF growth undermines predictability of internal funding and heightens dependence on balance sheet capacity. For a capital-intensive pharma group, inconsistent FCF complicates multi-year R&D planning and capital allocation decisions.
Inconsistent Year-to-year PerformanceMaterial swings in profitability across years reflect exposure to product life-cycle effects, investment cycles or one-off items. This lumpy performance increases forecasting risk, may pressure management trade-offs, and can delay sustainable margin visibility over multi-year horizons.
Otsuka Holdings Co News
4578 FAQ
What was Otsuka Holdings Co Ltd’s price range in the past 12 months?
Otsuka Holdings Co Ltd lowest stock price was ¥6511.00 and its highest was ¥11660.00 in the past 12 months.
What is Otsuka Holdings Co Ltd’s market cap?
Otsuka Holdings Co Ltd’s market cap is ¥6.02T.
When is Otsuka Holdings Co Ltd’s upcoming earnings report date?
Otsuka Holdings Co Ltd’s upcoming earnings report date is Jul 30, 2026 which is in 70 days.
How were Otsuka Holdings Co Ltd’s earnings last quarter?
Otsuka Holdings Co Ltd released its earnings results on Apr 28, 2026. The company reported ¥186.31 earnings per share for the quarter, beating the consensus estimate of ¥136.268 by ¥50.042.
Is Otsuka Holdings Co Ltd overvalued?
According to Wall Street analysts Otsuka Holdings Co Ltd’s price is currently Undervalued.
Does Otsuka Holdings Co Ltd pay dividends?
Otsuka Holdings Co Ltd pays a Semiannually dividend of ¥70 which represents an annual dividend yield of 1.42%. See more information on Otsuka Holdings Co Ltd dividends here
What is Otsuka Holdings Co Ltd’s EPS estimate?
Otsuka Holdings Co Ltd’s EPS estimate is 148.05.
How many shares outstanding does Otsuka Holdings Co Ltd have?
Otsuka Holdings Co Ltd has 542,988,900 shares outstanding.
What happened to Otsuka Holdings Co Ltd’s price movement after its last earnings report?
Otsuka Holdings Co Ltd reported an EPS of ¥186.31 in its last earnings report, beating expectations of ¥136.268. Following the earnings report the stock price went up 5.026%.
Which hedge fund is a major shareholder of Otsuka Holdings Co Ltd?
Currently, no hedge funds are holding shares in JP:4578
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Otsuka Holdings Co Ltd
Otsuka Holdings Co., Ltd. is a global healthcare company based in Japan, primarily engaged in the pharmaceutical and nutraceutical sectors. The company operates through two main segments: Pharmaceuticals, which focuses on the development of innovative drugs in areas such as central nervous system disorders, oncology, and cardiovascular health; and Nutraceuticals, which offers products designed to enhance health and wellness, including functional foods and beverages. Otsuka is known for its commitment to research and development, aiming to improve the quality of life through advanced medical solutions and nutritional products.
4578 Stock 12 Month Forecast
Average Price Target
¥12,458.00
▲(52.86% Upside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Daiichi Sankyo Company
―
Eisai Co
―
Takeda Pharmaceutical Co
―
Options Prices
Currently, No data available
---